The Use Of A Multidrug Pill In Reducing Cardiovascular Events (UMPIRE) Trial
Funder
National Health and Medical Research Council
Funding Amount
$314,535.00
Summary
Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Aust ....Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Australian researchers will have a pivotal role in collecting and interpreting the data in this trial. In addition, Australian researchers will combine the findings of this study with results from similar trials being conducted in Australia (1600 patients, including 600 Aboriginal participants) and New Zealand (600 patients, including 600 Maori participants). This overview will provide very accurate information about the usefulness of the polypill, and how it should be used worldwide.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$1,477,963.00
Summary
Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a ....Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a normal protein in the blood, are another major causal risk factor for atherosclerosis (and stroke and heart attacks). Furthermore, blood concentrations of homocysteine can be lowered by about one quarter with simple, safe and inexpensive multivitamin therapy (folic acid, vitamin B12, and vitamin B6). However, despite the potentially massive public health benefits of such a strategy, it remains to be demonstrated in properly designed clinical trials that lowering homocysteine levels in the blood actually prevents stroke and heart attack. The VITATOPS trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$470,887.00
Summary
The VITAmins To Prevent Stroke (VITATOPS) trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke. To date more than 7,500 patients have been randomised. Ongoing support is requested to complete the follow-up of 8,000 patients by middle of 2009.
Reducing Falls By Improving Knowledge Translation: A Mixed-methods Study To Incorporate Falls Prevention Best-practice Evidence Into Osteoarthritis Care
Funder
National Health and Medical Research Council
Funding Amount
$88,502.00
Summary
Over 50% of people with osteoarthritis (OA) will fall. Resources exist to assist clinicians in the management of OA, but give little or no attention to falls.The association between OA and falls supports the need to incorporate falls prevention strategies into routine OA care. This project aims to reduce falls and fall-related harm in people with OA by creating a list of recommendations for preventing falls that can be incorporated into current OA resources and routine OA care.
Better prevention and management of disabling back pain. This project will establish a program of back pain research within an inter-disciplinary research centre focused on the prevention and management of physical disability.
A Lifestyle Intervention Program For The Prevention Of Type 2 Diabetes Mellitus Among South Asian Women With Gestational Diabetes Mellitus
Funder
National Health and Medical Research Council
Funding Amount
$1,256,499.00
Summary
Gestational diabetes mellitus (GDM) is common in South Asian women, and many develop lifelong type 2 diabetes (T2DM) soon after delivery. Lifestyle change helps prevent T2DM, but we do not know how to introduce a sustainable service that will change lifestyles of young, busy and often poor women. We will test a unique intervention embedded within local health systems in 1414 women with GDM from 24 hospitals in South Asia, hoping to show that this intervention will prevent T2DM.
Should Australia Introduce A National Chlamydia Testing Program? Evaluation Of A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$518,510.00
Summary
Chlamydia is a very common sexually transmissible infection that can lead to infertility in women. About 4% of young adults have it, yet most are unaware they have it. Chlamydia is easy to diagnose and treat, but it is not known whether annual testing can reduce its spread. Over1 million tests are conducted each year in general practice, costing the government $30 million. This evaluation of a well-established trial of chlamydia testing in young adults will resolve the debate of whether annual t ....Chlamydia is a very common sexually transmissible infection that can lead to infertility in women. About 4% of young adults have it, yet most are unaware they have it. Chlamydia is easy to diagnose and treat, but it is not known whether annual testing can reduce its spread. Over1 million tests are conducted each year in general practice, costing the government $30 million. This evaluation of a well-established trial of chlamydia testing in young adults will resolve the debate of whether annual testing works and is a good use of money.Read moreRead less
Improving Health Outcomes With Ageing And Diabetes: A Focus On Prevention And Management Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
My research combines interventional trials, epidemiology and health services implementation research with a focus on prevention of cardiovascular disease, disability and dementia, including in the elderly and those with diabetes. With direct impact on the routine care of people who succumb to disabling vascular complications, it will evaluate treatment strategies but also influence change in health care and policy through the provision of trial evidence and evidence-based health services.
Examining the complexity of communication processes across transition points from the emergency department to improve medication safety. Problems in communication contribute significantly to adverse events that lead to serious harm for Australian consumers. Recent data show medication errors account for over 25% of all adverse events, while over 50% of consumers who move across transition points have medication errors relating to their treatment regimen. Financial costs from adverse events are e ....Examining the complexity of communication processes across transition points from the emergency department to improve medication safety. Problems in communication contribute significantly to adverse events that lead to serious harm for Australian consumers. Recent data show medication errors account for over 25% of all adverse events, while over 50% of consumers who move across transition points have medication errors relating to their treatment regimen. Financial costs from adverse events are estimated at around $A2billion/year, which are likely to increase with further complexities involving consumer care. This study will result in new knowledge about communication processes to inform the development of reporting methods and strategies, which positively influence the practices of health professionals in managing medications as consumers move across different environments.Read moreRead less